title: Dynamics of chemosensitivity and chromosomal instability in recurrent glioblastoma.
abstract: Glioblastoma multiforme is characterised by invasive growth and frequent recurrence. Here, we have analysed chromosomal changes in comparison to tumour cell aggressiveness and chemosensitivity of three cell lines established from a primary tumour and consecutive recurrences (BTL1 to BTL3) of a long-term surviving glioblastoma patient together with paraffin-embedded materials of five further cases with recurrent disease. Following surgery, the BTL patient progressed under irradiation/ lomustine but responded to temozolomide after re-operation to temozolomide. The primary tumour -derived BTL1 cells showed chromosomal imbalances typical of highly aggressive glioblastomas. Interestingly, BTL2 cells established from the first recurrence developed under therapy showed signs of enhanced chromosomal instability. In contrast, BTL3 cells from the second recurrence resembled a less aggressive subclone of the primary tumour. Although BTL2 cells exhibited a highly aggressive phenotype, BTL3 cells were characterised by reduced proliferative and migratory potential. Despite persistent methylation of the O6-methylguanine-DNA methyltransferase promoter, BTL3 cells exhibited the highest temozolomide sensitivity. A comparable situation was found in two out of five glioblastoma patients, both characterised by enhanced survival time, who also relapsed after surgery/chemotherapy with less aggressive recurrences. Taken together, our data suggest that pretreated glioblastoma patients may relapse with highly chemosensitive tumours confirming the feasibility of temozolomide treatment even in case of repeated recurrence.
authors.affiliation: Department of Neurosurgery, Wagner Jauregg Hospital, Linz, Austria.
authors.forename: S
authors.initials: S
authors.lastname: Spiegl-Kreinecker
authors.forename: C
authors.initials: C
authors.lastname: Pirker
authors.forename: C
authors.initials: C
authors.lastname: Marosi
authors.forename: J
authors.initials: J
authors.lastname: Buchroithner
authors.forename: J
authors.initials: J
authors.lastname: Pichler
authors.forename: R
authors.initials: R
authors.lastname: Silye
authors.forename: J
authors.initials: J
authors.lastname: Fischer
authors.forename: M
authors.initials: M
authors.lastname: Micksche
authors.forename: W
authors.initials: W
authors.lastname: Berger
mesh_terms: D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000235:genetics* / Q000532:radiotherapy / Q000601:surgery; D045744:Cell Line, Tumor; D043171:Chromosomal Instability; D003606:Dacarbazine / Q000031:analogs & derivatives / Q000627:therapeutic use; D019008:Drug Resistance, Neoplasm; D005260:Female; D005909:Glioblastoma / Q000188:drug therapy* / Q000235:genetics* / Q000532:radiotherapy / Q000601:surgery; D006801:Humans; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy* / Q000235:genetics* / Q000532:radiotherapy / Q000601:surgery; D009693:Nucleic Acid Hybridization / Q000379:methods; D000077204:Temozolomide
chemical_list: D018906:Antineoplastic Agents, Alkylating; D003606:Dacarbazine; D000077204:Temozolomide